The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease: Zileuton: 5-LO pathway inhibition
Open accessAbstract
The 5-Lipoxygenase pathway results in the formation of leukotrienes, including leukotriene B(4) (LTB(4)), 5-oxo-6E,8Z,11Z,14Z-eicosatetranoic acid and the cysteinyl leukotrienes (LTC(4), LTD(4) and LTE(4)) and activates all four leukotriene receptors, BLT1, BLT2, cysLT(1) and cysLT(2). Zileuton is the only commercially available inhibitor of the 5-Lipoxygenase pathway. In a number of clinical trials, zileuton has been shown to improve airway function and inflammation, asthma symptom control and quality of life in asthmatics. Given the important role that leukotrienes play in airway inflammation, zileuton provides an additional therapeutic option in the management of chronic, persistent asthma, particularly those asthmatics with more severe disease. In addition, zileuton has shown promise in a number of other conditions, including upper airway inflammatory conditions, dermatological disease and chronic obstructive pulmonary disease. The development of new formulations, including a controlled release tablet formulation for b.i.d. dosing and an intravenous preparation for acute asthma exacerbations may enhance clinical utility and expand therapeutic indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prostaglandins and Leukotrienes: Advances in Eicosanoid Biology
Funk, C. D. (2001) · Science · doi:10.1126/science.294.5548.1871 · Cited by 3,817
Lewis (1990) · doi:10.1056/nejm199009063231006 · Cited by 1,200
Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma
O'Byrne, P. M., Bisgaard, H., Godard, P. P., Pistolesi, M., Palmqvist, M., Zhu, Y., Ekström, T., & Bateman, E. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200407-884oc · Cited by 657
Cited by
Peters-Golden, M., & Henderson, W. R. (2007) · New England Journal of Medicine · doi:10.1056/nejmra071371 · Cited by 1,013
Mammalian lipoxygenases and their biological relevance
Kuhn, H., Banthiya, S., & van Leyen, K. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.10.002 · Cited by 624
Zhou, S.-F., Wang, B., Yang, L.-P., & Liu, J.-P. (2010) · Drug Metabolism Reviews · doi:10.3109/03602530903286476 · Cited by 262
Increased leukotriene E4 excretion in systemic mastocytosis
Butterfield, J. H. (2010) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2010.03.003 · Cited by 42
Metadata
- Authors
- Berger, W., De Chandt, M. T. M., & Cairns, C. B.
- Venue
- International Journal of Clinical Practice
- Publisher
- Hindawi Limited
- Published
- 2007-03-22
- Volume
- 61
- Issue
- 4
- Pages
- 663-676
- ISSN
- 1368-5031 (ISSN-L)
- OpenAlex
- W1712101512
- Cited by
- 205
- References
- 3
- FWCI
- 6.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease: Zileuton: 5-LO pathway inhibition. https://app.cochat.ai/papers/10.1111/j.1742-1241.2007.01320.x
- The paper
- Berger, W., De Chandt, M. T. M., & Cairns, C. B. (2007). Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease: Zileuton: 5-LO pathway inhibition. International Journal of Clinical Practice. https://doi.org/10.1111/j.1742-1241.2007.01320.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.